New Zealand Clinical Research (NZCR) is putting put out a call for healthy males in Auckland and Christchurch to be part of two large trials researching potential new treatments for breast cancer.
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab
biosimilar, in healthy adult subjects
